Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Alexander Kaminsky, Lauren M. Fahmy, Zaid Bilgrami, Hye Ryung Yang, Volkan Beylergil, Mengxi Zhou, Antonio T. Fojo, Susan E. Bates, Lawrence Schwartz, Larisa J Geskin

Blood (2024) 144 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2024-211442

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Sara Suhl, Alexander Kaminsky, Abigail Marx, Sophia Luyten, Ikenna David Nebo, Barbara Pro, Larisa J Geskin

Blood (2024) 144 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2024-212039

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome

Blood (2024) 143 (15): 1496–1512.

https://doi.org/10.1182/blood.2023021671

Published: 2024

Includes: Supplemental data

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis

Lauren M. Fahmy, Hye Ryung Yang, Mengxi Zhou, Volkan Beylergil, Celine M. Schreidah, Zaid Bilgrami, Bradley D. Kwinta, Lawrence Schwartz, Antonio T. Fojo, Susan E. Bates, Larisa J. Geskin

Blood (2023) 142 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2023-189493

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss

Blood (2022) 140 (Supplement 1): 6577–6578.

https://doi.org/10.1182/blood-2022-167564

Published: 2022

Journal Articles

Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis

Lauren Fahmy, Hye Ryung Yang, Bradley Kwinta, Volkan Beylergil, Celine M Schreidah, Lawrence H. Schwartz, Larisa J Geskin

Blood (2022) 140 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2022-163711

Published: 2022

Journal Articles

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures

Alberto Herrera, Anthony Cheng, Eleni P. Mimitou, Angelina Seffens, Dean George, Michal Bar-Natan, Adriana Heguy, Kelly V. Ruggles, Jose U. Scher, Kenneth Hymes, Jo-Ann Latkowski, Niels Ødum, Marshall E. Kadin, Zhengqing Ouyang, Larisa J. Geskin, Peter Smibert, Terkild B. Buus, Sergei B. Koralov

Blood (2021) 138 (16): 1456–1464.

https://doi.org/10.1182/blood.2020009346

Published: 2021

Includes: Supplemental data

Journal Articles

Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma

Alyxzandria M. Gaydosik, Dawn S. Queen, Megan H. Trager, Oleg E. Akilov, Larisa J. Geskin, Patrizia Fuschiotti

Blood (2020) 136 (15): 1748–1759.

https://doi.org/10.1182/blood.2019004725

Published: 2020

Includes: Supplemental data

Journal Articles

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Cosmin A Tegla, MD, Alberto M Herrera, MS, Angelina M Seffens, BS, Melania H Fanok, PhD, George Dean, MD, John Kawaoka, MD, Mary E Laird, MD, Yi Fulmer, PhD, Andreas Willerslev-Olsen, PhD, Kenneth B. Hymes, MD, Jo-Ann Latkowski, MD, Niels Odum, MD DMSci, Stefan Feske, MD, Bo Shopsin, MD PhD, Victor Torres, PhD, Marshall E. Kadin, MD, Larisa J Geskin, MD, Sergei B. Koralov, PhD

Blood (2019) 134 (Supplement_1): 659.

https://doi.org/10.1182/blood-2019-131917

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Youn H Kim, MD, Richard T. Hoppe, MD, Alain H Rook, MD, Amit Maity, MD PhD, Larisa J Geskin, MD, David P Horowitz, MD, Genet Finnegan, MHS, PA-C, Michael Khodadoust, MD PhD, Wen-Kai Weng, MD PhD, Analuisa Lares, ANP, BSN, RN, Eric Ki Jun Hong, BS, Marie Buchanan, RN, Vernon Ma, BS, Hue Kha, BS, Chris E Lawrence, PhD, Vladimir Vainstein, MD, Lena A Basile, PhD JD

Blood (2016) 128 (22): 4165.

https://doi.org/10.1182/blood.V128.22.4165.4165

Published: 2016

Journal Articles

Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Larisa J. Geskin, Sara Viragova, Donna B. Stolz, Patrizia Fuschiotti

Blood (2015) 125 (18): 2798–2805.

https://doi.org/10.1182/blood-2014-07-590398

Published: 2015

Includes: Supplemental data

Journal Articles

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Fiona Child, MD, Pablo Ortiz Romero, Prof., Rute Alvarez, MD, Martine Bagot, Rudolf Stadler, MD, Michael Weichenthal, MD, Rosario Alves, MD, Maria Grazia Bernengo, Prof., Marie Beylot-Barry, Prof., Richard Cowan, Larisa J. Geskin, MD, Amparo Pérez Ferriols, Peter Hellemans, MD, Yusri Elsayed, MD, PhD, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3676.

https://doi.org/10.1182/blood.V120.21.3676.3676

Published: 2012

Journal Articles

Multicenter Trial of Photopheresis in Early Stage Mycosis Fungoides

Madeleine Duvic, MD, Rakhshandra Talpur, MD, Elma D Baron, MD, Larisa J. Geskin, MD, Marie-France Demierre, MD, John Zic, MD, Kimberly Bohjanan, MD

Blood (2008) 112 (11): 4942.

https://doi.org/10.1182/blood.V112.11.4942.4942

Published: 2008

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sareeta Parker, Eric C. Vonderheid, Justin L. Ricker, Syed Rizvi, Cong Chen, Kathleen Boileau, Paulette Cooley, Larisa J. Geskin

Blood (2007) 110 (11): 2582.

https://doi.org/10.1182/blood.V110.11.2582.2582

Published: 2007

NARROW

Survival and Treatment Response in CTCL Can be Predicted Using Volumetric Lymph Node Size and Dynamic Changes in Lymph Node Size and Skin Score

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures

Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Multicenter Trial of Photopheresis in Early Stage Mycosis Fungoides

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only